Autism and thimerosal-containing vaccines: lack of consistent evidence for an association
- PMID: 12880876
- DOI: 10.1016/s0749-3797(03)00113-2
Autism and thimerosal-containing vaccines: lack of consistent evidence for an association
Abstract
Background: In 1999, concerns were raised that vaccines containing the preservative Thimerosal might increase the risk of autism and/or other neurodevelopmental disorders.
Methods: Between the mid-1980s through the late-1990s, we compared the prevalence/incidence of autism in California, Sweden, and Denmark with average exposures to Thimerosal-containing vaccines. Graphic ecologic analyses were used to examine population-based data from the United States (national immunization coverage surveys and counts of children diagnosed with autism-like disorders seeking special education services in California); Sweden (national inpatient data on autism cases, national vaccination coverage levels, and information on use of all vaccines and vaccine-specific amounts of Thimerosal); and Denmark (national registry of inpatient/outpatient-diagnosed autism cases, national vaccination coverage levels, and information on use of all vaccines and vaccine-specific amounts of Thimerosal).
Results: In all three countries, the incidence and prevalence of autism-like disorders began to rise in the 1985-1989 period, and the rate of increase accelerated in the early 1990s. However, in contrast to the situation in the United States, where the average Thimerosal dose from vaccines increased throughout the 1990s, Thimerosal exposures from vaccines in both Sweden and Denmark-already low throughout the 1970s and 1980s-began to decrease in the late 1980s and were eliminated in the early 1990s.
Conclusions: The body of existing data, including the ecologic data presented herein, is not consistent with the hypothesis that increased exposure to Thimerosal-containing vaccines is responsible for the apparent increase in the rates of autism in young children being observed worldwide.
Comment in
-
Concerns continue over mercury and autism.Am J Prev Med. 2004 Jan;26(1):91; reply 91-2. doi: 10.1016/j.amepre.2003.10.019. Am J Prev Med. 2004. PMID: 14700719 No abstract available.
Similar articles
-
An evaluation of the effects of thimerosal on neurodevelopmental disorders reported following DTP and Hib vaccines in comparison to DTPH vaccine in the United States.J Toxicol Environ Health A. 2006 Aug;69(15):1481-95. doi: 10.1080/15287390500364556. J Toxicol Environ Health A. 2006. PMID: 16766480
-
[Lack of association between thimerosal-containing vaccines and autism].Przegl Epidemiol. 2011;65(3):491-5. Przegl Epidemiol. 2011. PMID: 22184954 Polish.
-
Association between thimerosal-containing vaccine and autism.JAMA. 2003 Oct 1;290(13):1763-6. doi: 10.1001/jama.290.13.1763. JAMA. 2003. PMID: 14519711
-
Does thimerosal or other mercury exposure increase the risk for autism? A review of current literature.Acta Neurobiol Exp (Wars). 2010;70(2):187-95. doi: 10.55782/ane-2010-1790. Acta Neurobiol Exp (Wars). 2010. PMID: 20628442 Review.
-
Thimerosal-containing vaccines and autistic spectrum disorder: a critical review of published original data.Pediatrics. 2004 Sep;114(3):793-804. doi: 10.1542/peds.2004-0434. Pediatrics. 2004. PMID: 15342856 Review.
Cited by
-
Neurotoxicity of mercury: an old issue with contemporary significance.Adv Neurotoxicol. 2021;5:239-262. doi: 10.1016/bs.ant.2021.01.001. Epub 2021 Feb 2. Adv Neurotoxicol. 2021. PMID: 34263092 Free PMC article.
-
Systematic Assessment of Research on Autism Spectrum Disorder (ASD) and Mercury Reveals Conflicts of Interest and the Need for Transparency in Autism Research.Sci Eng Ethics. 2017 Dec;23(6):1691-1718. doi: 10.1007/s11948-017-9983-2. Sci Eng Ethics. 2017. Retraction in: Sci Eng Ethics. 2017 Dec;23(6):1689-1690. doi: 10.1007/s11948-015-9713-6. PMID: 29119411 Free PMC article. Retracted. Review.
-
Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders: Part A--medical results.BMC Clin Pharmacol. 2009 Oct 23;9:16. doi: 10.1186/1472-6904-9-16. BMC Clin Pharmacol. 2009. PMID: 19852789 Free PMC article. Clinical Trial.
-
Thiomersal in vaccines: balancing the risk of adverse effects with the risk of vaccine-preventable disease.Drug Saf. 2005;28(2):89-101. doi: 10.2165/00002018-200528020-00001. Drug Saf. 2005. PMID: 15691220 Review.
-
A Multi-Center Study on Sensitization to Thimerosal in North-Eastern Italy, 1997-2023: Prevalence, Risk Factors, the Role of Occupation and the Impact of Vaccinations.Vaccines (Basel). 2025 Jun 9;13(6):622. doi: 10.3390/vaccines13060622. Vaccines (Basel). 2025. PMID: 40573953 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical